{"id":"W4412426006","doi":"10.21203/rs.3.rs-7090131/v1","title":"Long-term survival after neoadjuvant low-dose ipilimumab plus high-dose nivolumab in resectable stage III melanoma: the 5-year survival-update and biomarker analysis from the PRADO-trial","year":2025,"lang":"en","type":"preprint","venue":"Research Square","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"Institute of Cancer Research","funders":"Les Laboratories Pierre Fabre; SkylineDx; Regeneron Pharmaceuticals; Eli Lilly and Company; Bristol-Myers Squibb; Amgen","keywords":"Nivolumab; Ipilimumab; Oncology; Medicine; Stage (stratigraphy); Internal medicine; Melanoma; Survival analysis; Overall survival; Immunotherapy; Cancer; Cancer research; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00245625,0.0006640716,0.001490615,0.0002001323,0.0002288987,0.001233055,0.0004401355,0.0006187818,0.001394418],"category_scores_gemma":[0.002179109,0.0002051622,0.00218216,0.0003582633,0.0004153898,0.0009123246,0.0004954214,0.001737653,0.0003820068],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008615925,"about_ca_system_score_gemma":0.000757106,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009311328,"about_ca_topic_score_gemma":0.003709926,"domain_scores_codex":[0.9993317,0.0003087737,0.00004617036,0.0001365767,0.00008272511,0.00009405863],"domain_scores_gemma":[0.9991788,0.00025977,0.0002095008,0.0001165403,0.00005902034,0.0001761948],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5226281,0.002675743,0.06540963,0.002796154,0.01508533,0.0002169479,0.0002509203,0.006039925,0.006710385,0.000881034,0.01976188,0.357544],"study_design_scores_gemma":[0.2025101,0.1254455,0.5686054,0.001940115,0.03725217,0.00105271,0.0004074106,0.007171541,0.004543288,0.005597322,0.04521113,0.0002632521],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9578536,0.03058021,0.0008103406,0.001761556,0.0007909235,0.0001754942,0.003750568,0.00005978029,0.00421752],"genre_scores_gemma":[0.9777039,0.007981434,0.0009389765,0.001830268,0.0005462688,0.0003057255,0.008063899,0.00005530219,0.002574162],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00245625,"threshold_uncertainty_score":0.01299006,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04338473399575225,"score_gpt":0.3649974045759101,"score_spread":0.3216126705801578,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}